Article info
Clinical and epidemiological research
Extended report
Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension
- Correspondence to Dr Edward Keystone, The Rebecca MacDonald Centre for Arthritis & Autoimmune Diseases, Mount Sinai Hospital, 60 Murray St., Room 2-006, Box 4, Toronto, ON, Canada M5T 3L9; edkeystone{at}mtsinai.on.ca
Citation
Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension
Publication history
- Received March 27, 2013
- Revised July 5, 2013
- Accepted July 15, 2013
- First published August 5, 2013.
Online issue publication
October 30, 2014
Article Versions
- Previous version (5 August 2013).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Files in this Data Supplement:
- Data supplement 1 - Online supplement
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/